M&A Deal Summary |
|
|---|---|
| Date | 2019-07-29 |
| Target | The Upjohn Company |
| Sector | Life Science |
| Buyer(s) | Viatris |
| Sellers(s) | Pfizer |
| Deal Type | Merger |
SEARCH BY
Try For Free 7-Day Free Trial
| Category | Company |
|---|---|
| Founded | 1961 |
| Sector | Life Science |
| Employees | 33,000 |
| Revenue | 15.4B USD (2023) |
Viatris is a generic and specialty pharmaceutical company. Viatris offers the industry's broadest and highest quality product portfolios, a robust product pipeline, and a global commercial footprint through operations in more than 90 countries. Viatris was founded in 1961 and is based in Canonsburg, Pennsylvania.
| DEAL STATS | # |
|---|---|
| Overall | 12 of 13 |
| Sector (Life Science) | 9 of 10 |
| Type (Merger) | 1 of 1 |
| State (Michigan) | 1 of 1 |
| Country (United States) | 6 of 6 |
| Year (2019) | 1 of 1 |
| DATE | TARGET | DEAL TYPE | VALUE |
|---|---|---|---|
| 2017-01-09 |
Cold-EEZE
Doylestown, Pennsylvania, United States Cold-EEZE is a cold remedy zinc gluconate lozenges are clinically proven to significantly reduce the duration of the common cold. |
Buy | - |
| DATE | TARGET | DEAL TYPE | VALUE |
|---|---|---|---|
| 2020-09-08 |
Aspen Pharmacare Holdings - Thrombosis Business
United Kingdom Aspen Pharmacare's Thrombosis Business is a global offering comprised largely of a broad range of specialist injectable anticoagulants. Aspen's portfolio also includes Orgaran which is a heparin derivative (heparinoid) indicated for the treatment of HIT. HIT is an adverse reaction occurring in a limited number of patients undergoing heparin related therapy. It offers healthcare providers the advantage of a single supplier that addresses broad clinical needs and thus ensures the optimal care of patients at risk of thrombosis. |
Buy | €642M |
| Category | Company |
|---|---|
| Founded | 1849 |
| Sector | Life Science |
| Employees | 8,300 |
| Revenue | 58.5B USD (2023) |
Pfizer is a global pharmaceutical company that is involved in the discovery, development, manufacture, and marketing of a wide range of healthcare products, including medicines and vaccines. The company's portfolio includes treatments across a broad spectrum of areas such as oncology, cardiology, neurology, and infectious diseases, among others. Pfizer was founded in 1849 and is based in New York, New York.
| DEAL STATS | # |
|---|---|
| Overall | 14 of 18 |
| Sector (Life Science) | 9 of 13 |
| Type (Merger) | 2 of 2 |
| State (Michigan) | 1 of 1 |
| Country (United States) | 10 of 13 |
| Year (2019) | 1 of 1 |
| DATE | TARGET | DEAL TYPE | VALUE |
|---|---|---|---|
| 2019-06-17 |
Array BioPharma
Boulder, Colorado, United States Array BioPharma, Inc. is a biopharmaceutical company focused on the discovery, development, and commercialization of targeted small molecule drugs to treat patients afflicted with cancer. Six Phase 3 studies on Array invented drugs, binimetinib (partnered with Novartis) and selumetinib (partnered with AstraZeneca), are currently enrolling patients with cancer. Array BioPharma, Inc. was formed in 1998 and is headquartered in Boulder, Colorado. |
Buy | $11.4B |
| DATE | TARGET | DEAL TYPE | VALUE |
|---|---|---|---|
| 2020-01-13 |
Pfizer - CK 1 Business
New York, New York, United States Pfizer, Inc. - CK 1 Business is a novel CNS-penetrant small molecule inhibitor of casein kinase 1 (CK1), for the potential treatment of patients with behavioral and neurological symptoms across various psychiatric and neurological diseases. |
Sell | $75M |
